Cargando…
Hypofractionated Radiotherapy for Resectable Pancreatic Ductal Adenocarcinoma: A World First in Response to COVID19
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547484/ http://dx.doi.org/10.1016/j.hpb.2022.05.727 |
| _version_ | 1784805273675759616 |
|---|---|
| author | Spiers, H.V. Liau, S.-S. |
| author_facet | Spiers, H.V. Liau, S.-S. |
| author_sort | Spiers, H.V. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9547484 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95474842022-10-11 Hypofractionated Radiotherapy for Resectable Pancreatic Ductal Adenocarcinoma: A World First in Response to COVID19 Spiers, H.V. Liau, S.-S. HPB (Oxford) Article Published by Elsevier Ltd. 2022 2022-10-08 /pmc/articles/PMC9547484/ http://dx.doi.org/10.1016/j.hpb.2022.05.727 Text en Copyright © 2022 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Spiers, H.V. Liau, S.-S. Hypofractionated Radiotherapy for Resectable Pancreatic Ductal Adenocarcinoma: A World First in Response to COVID19 |
| title | Hypofractionated Radiotherapy for Resectable Pancreatic Ductal Adenocarcinoma: A World First in Response to COVID19 |
| title_full | Hypofractionated Radiotherapy for Resectable Pancreatic Ductal Adenocarcinoma: A World First in Response to COVID19 |
| title_fullStr | Hypofractionated Radiotherapy for Resectable Pancreatic Ductal Adenocarcinoma: A World First in Response to COVID19 |
| title_full_unstemmed | Hypofractionated Radiotherapy for Resectable Pancreatic Ductal Adenocarcinoma: A World First in Response to COVID19 |
| title_short | Hypofractionated Radiotherapy for Resectable Pancreatic Ductal Adenocarcinoma: A World First in Response to COVID19 |
| title_sort | hypofractionated radiotherapy for resectable pancreatic ductal adenocarcinoma: a world first in response to covid19 |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547484/ http://dx.doi.org/10.1016/j.hpb.2022.05.727 |
| work_keys_str_mv | AT spiershv hypofractionatedradiotherapyforresectablepancreaticductaladenocarcinomaaworldfirstinresponsetocovid19 AT liauss hypofractionatedradiotherapyforresectablepancreaticductaladenocarcinomaaworldfirstinresponsetocovid19 |